Advanced search
1 file | 1.92 MB Add to list

Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders

Author
Organization
Project
Abstract
The complement system is implicated in a broad range of neuroinflammatory disorders such as Alzheimer's disease (AD) and multiple sclerosis (MS). Consequently, measuring complement levels in biofluids could serve as a potential biomarker for these diseases. Indeed, complement levels are shown to be altered in patients compared to controls, and some studies reported a correlation between the level of free complement in biofluids and disease progression, severity or the response to therapeutics. Overall, they are not (yet) suitable as a diagnostic tool due to heterogeneity of reported results. Moreover, measurement of free complement proteins has the disadvantage that information on their origin is lost, which might be of value in a multi-parameter approach for disease prediction and stratification. In light of this, extracellular vesicles (EVs) could provide a platform to improve the diagnostic power of complement proteins. EVs are nanosized double membrane particles that are secreted by essentially every cell type and resemble the (status of the) cell of origin. Interestingly, EVs can contain complement proteins, while the cellular origin can still be determined by the presence of EV surface markers. In this review, we summarize the current knowledge and future opportunities on the use of free and EV-associated complement proteins as biomarkers for neuroinflammatory and neurodegenerative disorders.
Keywords
complement, extracellular vesicle (EV), biomarker, neuroinflammation, Alzheimer's disease, multiple sclerosis, PLASMA CLUSTERIN CONCENTRATION, CEREBROSPINAL-FLUID ANALYSIS, MULTIPLE-SCLEROSIS PATIENTS, GENOME-WIDE ASSOCIATION, ALZHEIMERS-DISEASE, FACTOR-H, TERMINAL COMPONENT, IDENTIFIES VARIANTS, COGNITIVE DECLINE, EARLY VALIDATION

Downloads

  • 4917 23Burgelman.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.92 MB

Citation

Please use this url to cite or link to this publication:

MLA
Burgelman, Marlies, et al. “Free Complement and Complement Containing Extracellular Vesicles as Potential Biomarkers for Neuroinflammatory and Neurodegenerative Disorders.” FRONTIERS IN IMMUNOLOGY, vol. 13, 2023, doi:10.3389/fimmu.2022.1055050.
APA
Burgelman, M., Dujardin, P., Vandendriessche, C., & Vandenbroucke, R. (2023). Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders. FRONTIERS IN IMMUNOLOGY, 13. https://doi.org/10.3389/fimmu.2022.1055050
Chicago author-date
Burgelman, Marlies, Pieter Dujardin, Charysse Vandendriessche, and Roosmarijn Vandenbroucke. 2023. “Free Complement and Complement Containing Extracellular Vesicles as Potential Biomarkers for Neuroinflammatory and Neurodegenerative Disorders.” FRONTIERS IN IMMUNOLOGY 13. https://doi.org/10.3389/fimmu.2022.1055050.
Chicago author-date (all authors)
Burgelman, Marlies, Pieter Dujardin, Charysse Vandendriessche, and Roosmarijn Vandenbroucke. 2023. “Free Complement and Complement Containing Extracellular Vesicles as Potential Biomarkers for Neuroinflammatory and Neurodegenerative Disorders.” FRONTIERS IN IMMUNOLOGY 13. doi:10.3389/fimmu.2022.1055050.
Vancouver
1.
Burgelman M, Dujardin P, Vandendriessche C, Vandenbroucke R. Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders. FRONTIERS IN IMMUNOLOGY. 2023;13.
IEEE
[1]
M. Burgelman, P. Dujardin, C. Vandendriessche, and R. Vandenbroucke, “Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders,” FRONTIERS IN IMMUNOLOGY, vol. 13, 2023.
@article{01GYEXT0ETSZC7A2MTHHKDE7KW,
  abstract     = {{The complement system is implicated in a broad range of neuroinflammatory disorders such as Alzheimer's disease (AD) and multiple sclerosis (MS). Consequently, measuring complement levels in biofluids could serve as a potential biomarker for these diseases. Indeed, complement levels are shown to be altered in patients compared to controls, and some studies reported a correlation between the level of free complement in biofluids and disease progression, severity or the response to therapeutics. Overall, they are not (yet) suitable as a diagnostic tool due to heterogeneity of reported results. Moreover, measurement of free complement proteins has the disadvantage that information on their origin is lost, which might be of value in a multi-parameter approach for disease prediction and stratification. In light of this, extracellular vesicles (EVs) could provide a platform to improve the diagnostic power of complement proteins. EVs are nanosized double membrane particles that are secreted by essentially every cell type and resemble the (status of the) cell of origin. Interestingly, EVs can contain complement proteins, while the cellular origin can still be determined by the presence of EV surface markers. In this review, we summarize the current knowledge and future opportunities on the use of free and EV-associated complement proteins as biomarkers for neuroinflammatory and neurodegenerative disorders.}},
  articleno    = {{1055050}},
  author       = {{Burgelman, Marlies and Dujardin, Pieter and Vandendriessche, Charysse and Vandenbroucke, Roosmarijn}},
  issn         = {{1664-3224}},
  journal      = {{FRONTIERS IN IMMUNOLOGY}},
  keywords     = {{complement,extracellular vesicle (EV),biomarker,neuroinflammation,Alzheimer's disease,multiple sclerosis,PLASMA CLUSTERIN CONCENTRATION,CEREBROSPINAL-FLUID ANALYSIS,MULTIPLE-SCLEROSIS PATIENTS,GENOME-WIDE ASSOCIATION,ALZHEIMERS-DISEASE,FACTOR-H,TERMINAL COMPONENT,IDENTIFIES VARIANTS,COGNITIVE DECLINE,EARLY VALIDATION}},
  language     = {{eng}},
  pages        = {{27}},
  title        = {{Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders}},
  url          = {{http://doi.org/10.3389/fimmu.2022.1055050}},
  volume       = {{13}},
  year         = {{2023}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: